Cytokinetics, Inc. (CYTK)
71.93
+0.53
(+0.74%)
USD |
NASDAQ |
Sep 02, 16:00
72.93
+1.00
(+1.39%)
After-Hours: 06:51
Cytokinetics Research and Development Expense (TTM) : 384.41M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 384.41M |
| March 31, 2026 | 400.51M |
| December 31, 2025 | 405.90M |
| September 30, 2025 | 395.61M |
| June 30, 2025 | 381.26M |
| March 31, 2025 | 348.18M |
| December 31, 2024 | 329.88M |
| September 30, 2024 | 317.27M |
| June 30, 2024 | 315.75M |
| March 31, 2024 | 318.96M |
| December 31, 2023 | 316.36M |
| September 30, 2023 | 310.00M |
| June 30, 2023 | 289.96M |
| March 31, 2023 | 264.68M |
| December 31, 2022 | 232.41M |
| September 30, 2022 | 200.95M |
| June 30, 2022 | 182.87M |
| March 31, 2022 | 163.64M |
| December 31, 2021 | 150.30M |
| September 30, 2021 | 138.24M |
| June 30, 2021 | 119.34M |
| March 31, 2021 | 104.81M |
| December 31, 2020 | 95.12M |
| September 30, 2020 | 84.31M |
| June 30, 2020 | 80.88M |
| Date | Value |
|---|---|
| March 31, 2020 | 83.52M |
| December 31, 2019 | 85.73M |
| September 30, 2019 | 91.07M |
| June 30, 2019 | 92.23M |
| March 31, 2019 | 89.80M |
| December 31, 2018 | 88.39M |
| September 30, 2018 | 91.36M |
| June 30, 2018 | 94.91M |
| March 31, 2018 | 93.14M |
| December 31, 2017 | 90.30M |
| September 30, 2017 | 82.82M |
| June 30, 2017 | 75.74M |
| March 31, 2017 | 70.15M |
| December 31, 2016 | 64.40M |
| September 30, 2016 | 58.87M |
| June 30, 2016 | 52.56M |
| March 31, 2016 | 50.98M |
| December 31, 2015 | 46.40M |
| September 30, 2015 | 41.93M |
| June 30, 2015 | 41.79M |
| March 31, 2015 | 40.89M |
| December 31, 2014 | 44.43M |
| September 30, 2014 | 49.47M |
| June 30, 2014 | 51.50M |
| March 31, 2014 | 52.11M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Bristol Myers Squibb Co. | 9.548B |
| Krystal Biotech, Inc. | 53.39M |
| Ionis Pharmaceuticals, Inc. | 923.08M |
| Vertex Pharmaceuticals, Inc. | 3.907B |
| Alnylam Pharmaceuticals, Inc. | 1.509B |